• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

microRNA inhibitor shows promise in the treatment of Hepatitis C

bys25qthea
March 27, 2013
in Chronic Disease, Gastroenterology, Infectious Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

[tabs tab1=”2MM Rundown” tab2= “2MM Full Report”]

[tab]

Image: PD

1. Miravirsen, an antisense inhibitor of a microRNA that prevents degradation of HCV, produced a dose-dependent and prolonged decrease in HCV RNA levels in patients with chronic HCV genotype 1 infection. 

Miravirsen produced a dose-dependent and prolonged decrease in HCV RNA levels in patients with chronic HCV genotype 1 infection in this study. Miravirsen is a 15–nucleotide locked nucleic acid-modified antisense oligonucleotide which binds and sequesters miR-122. miR-122 is a liver micro RNA which complexes with the HCV genome, protecting it from nucleolytic degradation and innate immune responses. Thus, miravirsen exposes the HCV genome to host immune defenses. This stage IIa clinical trial demonstrates miravirsen’s advantages over current therapy including an improved side effect profile, reduced drug-drug interactions, no signs of resistance and once a month dosing.

Miravirsen is a promising new treatment for chronic HCV infection that could shorten treatment time, reduce the rate of relapse and offer the possibility of interferon-free regimens. However, due to its duration, this study could not identify long-term side effects of treatment. One of miR-122’s endogenous roles is as a tumor suppressor for hepatocellular carcinoma; therefore, long-term safety data for miravirsen are essential.

RELATED REPORTS

#VisualAbstract: Avatrombopag is an Effective Treatment for Children and Adolescents with Immune Thrombocytopenia

2 Minute Medicine Rewind June 9, 2025

Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis

Click to read the study, published today in NEJM

[/tab]

[tab] 

Image: PD

1. Miravirsen, an antisense inhibitor of a microRNA that prevents degradation of HCV, produced a dose-dependent and prolonged decrease in HCV RNA levels in patients with chronic HCV genotype 1 infection. 

This [randomized, double-blind, placebo–controlled] phase IIa dose-finding trial treated 36 therapy naïve HCV genotype 1 patients with compensated liver disease due to HCV, and a plasma HCV RNA level of more than 75,000 IU per milliliter, with miravirsen or placebo.  A total of 24 patients were treated with 3 mg, 5 mg or 7 mg/kg miravirsen (9 patients/group) subcutaneously in five weekly doses over a 29 day period. Patients were followed for a total of 18 weeks. Treatment with miravirsen resulted in a significant dose-dependent reduction in HCV RNA levels which was sustained beyond the administration of the drug. In five patients, miravirsen resulted in undetectable HCV RNA.

Virologic rebound was detected in 9 of 24 patients after discontinuation of miravirsen. However no resistance-associated mutations were detected In the HCV genome of any miravirsen patients. Most adverse events reported were mild, and there were no dose–dependent toxic effects or treatment discontinuation because of adverse effects. There was a sustained reduction in liver transaminases.

In sum: Miravirsen produced a dose-dependent and prolonged decrease in HCV RNA levels in patients with chronic HCV genotype 1 infection. Miravirsen is a 15–nucleotide locked nucleic acid-modified antisense oligonucleotide which binds and sequesters miR-122. miR-122 is a liver micro RNA which complexes with the HCV genome, protecting it from nucleolytic degradation and innate immune responses. Thus, miravirsen exposes the HCV genome to host immune defenses. This stage IIa clinical trial demonstrates miravirsen’s advantages over current therapy including an improved side effect profile, reduced drug-drug interactions, no signs of resistance and once a month dosing.

Miravirsen is a promising new treatment for chronic HCV infection that could shorten treatment time, reduce the rate of relapse and offer the possibility of interferon-free regimens. However, due to its duration, this study could not identify long-term side effects of treatment. One of miR-122’s endogenous roles is as a tumor suppressor for hepatocellular carcinoma; therefore, long-term safety data for miravirsen are essential.

Click to read the study, published today in NEJM 

By Jessica Mitchell and Mitalee Patil

More from this author: Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production of cortisol, Ischemic heart disease increases linearly with radiotherapy for breast cancer, Ondansetron (Zofran) is safe for treatment of nausea in pregnancy, Dabigatran is noninferior to warfarin for VTE

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

[/tab]

[/tabs]

Previous Post

Sublingual immunotherapy may be safe and effective for asthma and allergic rhinoconjunctivitis

Next Post

Rhinovirus, genes may interact to increase the risk of childhood asthma

RelatedReports

#VisualAbstract: Avatrombopag is an Effective Treatment for Children and Adolescents with Immune Thrombocytopenia
StudyGraphics

#VisualAbstract: Avatrombopag is an Effective Treatment for Children and Adolescents with Immune Thrombocytopenia

June 9, 2025
Weekly Rewinds

2 Minute Medicine Rewind June 9, 2025

June 9, 2025
Being overweight and obese associated with increased incidence of chronic kidney disease
Emergency

Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis

June 5, 2025
Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Cardiology

Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension

June 5, 2025
Next Post
Rhinovirus, genes may interact to increase the risk of childhood asthma

Rhinovirus, genes may interact to increase the risk of childhood asthma

Physical therapy equal to surgery for symptomatic meniscal tears

Physical therapy equal to surgery for symptomatic meniscal tears

Radiosurgery safe and effective for unruptured intracranial AVMs

Radiosurgery safe and effective for unruptured intracranial AVMs

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Avatrombopag is an Effective Treatment for Children and Adolescents with Immune Thrombocytopenia
  • 2 Minute Medicine Rewind June 9, 2025
  • Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.